Comparison of Two Different Doses of Bemiparin in COVID-19
Status:
Recruiting
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
Patients requiring hospitalization due to COVID-19 pneumonia (non-severe) will be randomized
to standard prophylactic doses or full therapeutic dose of bemiparin (a LMWH) for 10 days.
Phase:
Phase 3
Details
Lead Sponsor:
Clinica Universidad de Navarra, Universidad de Navarra